(158) have designed a bidirectional deactivated RfxCas13d (dCasRx)-based m6A-editing platform that comprises the catalytic domains of METTL3 or ALKBH5 to manipulate the m6A demethylation of ITGA6 mRNA, thereby inhibiting BLCA cell growth. Here, ITGA6 is linked to bladder transitional cell carcinoma.